The recurrent loss of genetic material from a specific chromosomal region in a given tumor type suggests the presence of a tumor-suppressor gene, the loss or inactivation of which may be relevant for tumorigenesis. In this study, we provide molecular evidence for the recurrent association between deletions on the long arm of chromosome 6 and B-cell non-Hodgkin lymphoma (B-NHL). Normal and tumor DNAs from 71 cases of B-NHL were studied for loss of constitutional heterozygosity (LOH) at 19 loci on chromosome 6 using a panel of restriction fragment length polymorphism (RFLP) probes. LOH, indicating deletion of all or part of 6q. was detected in 16 of 71 cases (22.5%). ranging from low-ONRANDOM CHROMOSOMAL deletions in hu-
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N man tumors reflect the loss of genetic information at specific sites in the genome and suggest the presence of tumor-suppressor genes, the inactivation of which may be relevant for tumor pathogene si^.'-^ The detailed analysis of tumor-associated deletions has led to the identification of a number of tumor-suppressor genes, which, if mutated or lost, relieve the cell from negative regulatory growth signals.14 The loss or inactivation of the tumor-suppressor genes p53 and RB1, for example, is frequently associated with a variety of human malignancies, including carcinomas, sarcomas, and hematopoietic t~m 0 r s . l .~
In the case of human lymphoid neoplasms, evidence has recently been acquired for a pathogenetic role of tumorsuppressor genes. 5 The p.53 gene is mutated and/or lost in a sizable fraction of Burkitt lymphomas (BL) and B-cell chronic lymphocytic leukemias. 6 In addition, RB1 lesions have also been documented in lymphoid tumors, although at low f r e q~e n c y .~,~ Evidence from various cytogenetic studies has suggested that deletions of the long arm of chromosome 6 represent recurrent abnormalities in various lymphoid malignancies, as well as in solid tumors, including malignant melanoma, renal cell carcinoma, and salivary gland adenocarcinoThese abnormalities include primarily deletions, and less frequently unbalanced translocations and 6p isochromosomes [i(6p)], which all lead to the loss of all or part of 6q. Although the reported frequency of 6q cytogenetic abnormalities in lymphoid malignancies varies among studies,y-11J3J5-1y these lesions are associated with the entire spectrum of lymphoid neoplasia, being particularly frequent in acute lymphoblastic leukemia (ALL) and B-cell non-Hodgkin lymphoma (B-NHL). The relevance of 6q loss in the pathogenesis of lymphoid neoplasia is strengthened by the observations that 6q deletions are sometimes the sole cytogenetic abnormality in a subset of t~m o r s ,~~, *~,~ are detectable at d i a g n~s i s ,~~.~~ and correlate with a poor prognosis. 26 Despite the abundance of cytogenetic studies documenting 6q deletions in B-NHL, little is known about the specific genomic regions involved, due to the relatively limited power of resolution of the cytogenetic analysis. In particular, no information is available on whether one or more grade to high-grade B-NHL. The isolated loss of 6p or the loss of ather chromosomes (8, 17, %22) tested as controls for specificity was not observed in any case. Comparison of the extent of the deletions among different cases allowed the identification of two distinct regions of minimal deletion (RMD) at 6q25 to 6q27 (RMD-1) apd at 6q21 to 6q23 (RMD-2). respectively, suggesting the existence of two tumor-suppressor genes. These data support a role for 6q deletions in B-NHL pathogenesis and provide a basis for identifying the corresponding tumor-suppressor genes. specific regions are consensually lost in different tumor cases, suggesting the involvement of specific genetic loci. As a first step toward the definition of these deletions, we have used the loss of heterozigosity (LOH) analysis to define the minimal deleted region in 6q in a panel of 71 B-NHL cases. We report that 6q deletions are detectable in 22.5% (16 of 71) of B-NHL cases and involve two discrete regions of the chromosome.
MATERIALS AND METHODS
Tumor biopsies. NHL samples from 57 patients were collected during standard diagnostic procedures. In all cases, the fraction of malignant cells in the pathologic specimen was at least 70%, as determined by cytofluorimetric analysis of cell-surface markers and antigen-receptor gene rearrangement analysis."
The following BL cell lines were used in the present study: BL02, BL30, BL38, BL108, BL113, BL53, BL29, BL60, BL44, BL74, BL135, BL116,28 and Wan.BL, Mutu.BL (kind gift of Dr A.B. Rickinson).
Normal tissue samples corresponding to each case of B-NHL studied were obtained from one of the following sources: peripheral blood (when not invaded by the malignant and 2 pgimLcyclosporine A (Sandoz, East Hanover, NJ) and cultured for 21 days at 37"C, 5% C02. After 3 weeks, cyclosporine A was removed from the culture medium and cell lines were expanded in culture conditions as described above, except for 10% FCS. Prior to LOH studies, a clonal analysis was performed by analysis of antigen-receptor gene rearrangements in paired tumoriLCL DNAs.?' In all cases, the neoplastic clone could not be detected by Southern blot analysis in the LCL, indicating that the tumor DNA was absent or below detectable levels ( < 5 % ) .
DNA extraction and Southem blotting. Genomic DNA was prepared by cell lysis, proteinase K digestion, "salting out" extraction, and ethanol precipitation as described.2y For Southern blot analysis,3" 5 pg of DNA was digested with the appropriate restriction endonuclease, electrophoresed in a 0.8% to 1% agarose gel, denatured, neutralized, transferred to Duralose filters (Stratagene, La Jolla, CA), and hybridized to probes that had been labeled with 32P by random primer extension.31 Filters were washed in 0 . 2~ SSC ( l x SSC = 0.15 mol/L NaCl + 0.015 mol/L sodium citrate)/0.5% sodium dodecyl sulfate (SDS) for 2 hours at 60"C, and then autoradiographed using intensifying screens (Quanta 111, Dupont, Boston, MA).
The main characteristics of the chromosome &specific polymorphic DNA markers used as probes, as well as markers located on other chromosomes and used in this study, have been previously d e~c r i b e d~~-~~; the various loci, their chromosomal localizations, and restriction enzymes used to detect their respective restriction fragment length polymorphism (RFLP) sites are listed in Table 1 . The following clones were obtained from the American Type Culture Collection (Rockville, MD): p3B10, pUCh-GIFR16', pHM2.6, pOR3, pB1.4, pJCZ30, pTHH5, pHHH157, pEFD6, pMCT128.2, and pYNZ22.1. Clone CRI-L994 was purchased from Collaborative Research (Bedford, MA). Probes p327A, HCNRp5, pCGa, phMnSOD4,616B, pCV6, pSVLhMPR5, JES-Vi-56-5, and T66H were a kind gift of Drs J. Klein, T.I. Bonner, I. Boime, G.I. Bell, S. Cederbaum, 0. Turunen, W.S. Sly, J.C. Murray, and R. Spielman, respectively. The chromosomal localizations of most of these markers have been previously r e p~r t e d~* ,~~ or have been obtained through the Genome Data Bank (GDB). In addition, the following loci have been mapped by us using fluorescent in situ hybridization: MYB, D6S32, D6S33, D6S37, and D6S39 (P.H.R. and R.S.K.C., unpublished data, March 1992).
Chromosome preparations of fresh tumor biopsies were obtained following disaggregation of tumor cells and short-term culture as described previously by us.1y In the case of established cell lines, high-resolution banding patterns were obtained following inhibition of chromosome condensation by treatment with ethidium bromide as described.M Q-and/or G-banding was applied following standard methods. Clonal chromosome abnormalities were defined and described according to ISCN.41 Probes.
Cytogenetic analysis. IN NON-HODGKIN of a small percentage of normal cells infiltrating the tumor biopsy) of one allele in tumor versus normal DNA. The frequency of LOH at each locus is shown in Table 1 . All but one case were informative for at least three 6q loci, and all were informative for at least one locus. Deletions involving 6q or the entire chromosome 6 were detected in 16 of 71 samples (22.5%), including all grades (low, intermediate, and high) of B-NHLs classified according to the Working Formulation!* 6p LOH was detectable in 3 of 49 (6.1%) informative cases, although never in the absence of 6q LOH. To discriminate whether 6q deletions represented a specific event in B-NHL, or were the effect of a general chromosomal instability affecting the whole genome, the LOH strategy was applied to loci mapping on chromosomes other than 6 and not known to represent deletion hotspots in these tumors (chromosomes 8, 17, and 22 for low-and intermediate-grade B-NHL; chromosomes 8 and 22 for high-grade B-NHL). No chromosomal loss was detected at any of the loci tested (Table 1) . These observations confirm that deletions represent a nonrandom event specifically affecting 6q.
The regions deleted in each B-NHL case are shown diagramatically in Fig 2; while some cases showed extensive deletions, affecting all the informative loci studied, in other cases LOH was restricted to a subset of loci. The comparative analysis of the LOH data in different cases allows the identification of two regions of minimal deletion (RMDs ;  Fig 2) . The first (RMD-1) is epitomized by the deletion of BL74 (Figs 1A and 2) and is located in the distal region of 6q, spanning bands 6q25 to 6q27. The limits of RMD-1 are defined by the 6q telomere distally, and the loci MYB and D6S33 proximally (Fig 2) . Interestingly, three cases with RMD-1 deletion (DK416, RC973, and BLO2; see Fig 2) display loss of some (D6S37 in DK416 and RC973; PLG and ESR in BLO2), but not all (IGF2-R, PLG, and ESR were retained in DK416 and RC973; D6S37 and D6S39 were retained in BLO2) markers in the 6q25 to 6q27 region, suggesting a further restriction of RMD-1. The second region (RMD-2) is centromeric to RMD-1 and appears to lie between SOD2 (6q21) and a cluster of loci (MYB, D6S33, IFNyR-1) mapping in the 6q23 and 6q24 area. Its telomeric border is defined by the distal breakpoint displayed by DK2927 (Fig 2) , while its centromeric limit corresponds to the proximal limit of the deletion of RC947 (Fig 2) .
The deletions observed among B-NHLs displayed different patterns of RMD involvement (Fig 2) : in some samples, the deletion was restricted to either RMD-1 or RMD-2; in other samples, both RMDs were affected, either as a result of a large deletion of the long arm (eg, RC1068) or as the independent loss of both regions (BL108 and DK867; Fig 2) with retention of intervening markers. However, in this last Comparison of LOH analysis with cytogenetic analysis. To confirm the LOH results by an independent method, cytogenetic analysis was performed in selected cases that had or had not shown 6q deletions by the LOH approach (Table 3 ; see Fig 3 for representative examples) . Of the 71 cases subjected to LOH studies, cytogenetic analysis was attempted in 15 samples (RC1251, RC973, RC492, RC1068, RC947, RC955, RC1029, RC1044, RC1081, BL02, BL30, BL38, BL74, BL108, and BL113). Of these, RC1251 and RC973 were cytogenetic failures, RC492 yielded normal chromosomes only, and the remaining were clonally abnormal. In one case (BL38), the deletion was detected only by cytogenetic analysis (Table 3 and Fig 3) , most likely due to the lack of informative loci within the deletion observed in this case. Five cases (BL02, BL113, BL108, RC1068, and RC947), which had shown 6q LOH by the molecular analysis (Fig 2) , also displayed 6q alterations at the cytogenetic level (Table 3 and Fig 3) . In these cases, the molecular analysis allows a more precise definition of the regions involved (RMD-1, RMD-2, or both) in the deletion than allowed by analysis of the microscopic level. Four cases (RC955, RC1029, RC1044, and RC1081), which had not Table 1 for precise mapping of each locus). Each locus is arbitrarily positioned within each cluster. The area of the boxes varies t o compensate for variable probe density within each cluster. 0, Retained heterozygosity; ., loss of heterozygosity; B, noninformative [homozygous) loci. Some cases show LOH at each informative locus on 6q (eg, RC1068) or on both 6q and 6p (eg, DK2150). thus suggesting the presence of an extensive deletion affecting the long arm or a chromosome 6 monosomy, respectively. In contrast, other B-NHL samples show a pattern of LOH restricted t o some 6q markers, allowing the identification of RMD-1 and RMD-2 (see text).
shown LOH at any 6q locus, did not show any 6q cytogenetic abnormality. Finally, BL74, which displayed two cytogenetically intact chromosomes 6 (Table 3 and Fig 3) , showed LOH of markers (D6S37 and TCP-10; see For mapping in the peritelomeric region, suggesting the presence of a small deletion that could not be detected at the microscopic level.
DISCUSSION
This study provides a molecular characterization of 6q deletions, which previous cytogenetic e v i d e n~e~-" . ' "~~.~.~~ has suggested to be consistently associated with B-NHL. The results confirm the cytogenetic data in terms of frequency of the lesion and provide evidence for the existence of two distinct regions of deletion and, therefore, two putative tumor-suppressor genes.
The 6q-lesion has been found in all grades of B-NHL42 at a frequency of 22.5%, in general agreement with that reported by previous cytogenetic observation^^".'"^^.^^ However, the real frequency of 6q deletions among B-NHL may still be underestimated, since our panel did not include immunoblastic lymphomas, which are reported to carry 6q deletions at particularly high frequency." In addition, tumors in which the deletion represented a subclonal event occurring in a minority of the cell population or which did not show informative loci within the deleted region, would be scored as normal by the LOH assay. Finally, one might predict a higher frequency of 6q loss to be detected when probing B-NHL with genetic markers more closely linked to the putative gene(s) involved.
Our results show that 6q losses in B-NHL cluster in two discrete RMDs. Based on the available mapping data of the markers delimiting the RMDs32,39 (see GDB and our unpublished observations), RMD-1 corresponds to bands 6q25 to 6q27, and RMD-2 to bands 6q21 to 6q23, suggesting the presence of two distinct tumor-suppressor genes. Depending on the extent of the deletion in different B-NHL samples, the observed lesion was restricted to one RMD or encompassed both RMD-1 and RMD-2. In some cases, both regions were independently lost, with retention of intervening markers such as c-myb, as previously r e~r t e d . 4~ These last cases might represent the molecular counterpart of the cytogenetic observation that two breakpoints on 6q (at 6q24 and at 6q14) may occur in the same B-NHL patient.17" A pattern of similar complexity has been described in the case of 3p deletions in renal cell carcinowhich are grouped within at least two discrete RMDs, and which may be present in the same patient with conservation of intervening chromosomal material.
RMD-2 partially overlaps with the RMD described in cytogenetic analysis of 6q deletions occurring in ALL.Is It remains to be defined whether the inactivation of the same locus is associated with the two diseases. While there are no obvious candidate tumor-suppressor genes in this area, two tyrosine kinase proto-oncogenes (ROS and FYN) with oncogenic potential are located in this However, ROS is not expressed in lymphoid tissue^^^,^^ and can be excluded as a candidate tumor-suppressor gene; FYN plays an important role in B-cell signal transduction,* yet its potential involvement in a recessive oncogenic mechanism appears problematic.
The presence of deletions restricted to 6q25 to 6q27 (RMD-1) in B-NHL represents a novel finding that was not evident from previously available cytogenetic examination. However, recent cytogenetic analysis of a large panel of B-NHLs (not including cases presented in this study) confirms that 6q25 to 6q27 is a RMD in B-NHL (unpublished observations). Our data suggest that the 6q25 to 6q27 region might be further resolved by the analysis of cases, such as DK416, RC973, and BLO2 (Fig 2) , which show LOH at some, but not all, loci mapping within 6q25 to 6q27. Interestingly, the same region has also been defined as the RMD of the 6q deletions that frequently occur in malignant melanoma,12.m renal cell carcinoma,2' and salivary gland adenocar~inoma,~~ although it cannot be predicted whether the same gene is involved in these different tumor types.
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Growth factor receptors (IGF2R, ESR), as well as known proto-oncogenes (MAS), map in this area,32 although there is presently no rationale to suggest their direct involvement in lymphomagenesis.
The results of the molecular characterization of 6q deletions are further supported by the comparison with cytogenetic analysis in cases for which both experimental approaches have been performed; it is of note, however, that LOH analysis may detect small deletions (see BL74; Figs 1A and 2), which are critical for the definition of the RMD limits and which are below the power of resolution of conventional cytogenetic techniques (see BL74 ; Fig 3) .
The results of LOH analysis reported here, together with available cytogenetic data, strongly support the notion that 6q is the site of tumor-suppressor genes relevant to B-cell lymphomagenesis. Although our study has identified the regions where the relevant genes are most likely to be found, the size of these regions is still relatively large, probably encompassing megabases of DNA.49 Further definition of the deleted regions and progress toward the identification of the involved genes will require further LOH studies using additional RFLP probes, as well as the construction of a physical map of the two areas. However, our data already allow the rationale design of simple RFLP-based assays for the identification of deletions involving RMD-1 and RMD-2, which can be used to investigate more precisely the relationship between each of these deletions and B-NHL histology, tumor progression, and clinical course.
